1	Coronary Artery anomalies in PatienTs Undergoing transcatheter
2	aortic valve REplacement.
3	The CAPTURE registry
4	
5	Omar A. Oliva ¹ , MD; Lorenzo Scalia ¹ , MD; Antonio Sisinni ¹ , MD; Enrico Poletti ¹ , MD; Jessica
6	Zannoni ¹ , MD; Mattia Mazzucca ¹ , MD; Enrico Criscione ¹ , MD; Antonio Popolo Rubbio ¹ , MD;
7	Riccardo Gorla ¹ , MD, PhD; Mauro Agnifili ¹ , MD; Francesco Bedogni ¹ , MD; Luca Testa ¹ , MD, PhD.
8	
9 10 11	¹ Department of Clinical and Interventional Cardiology, IRCCS Policlinico San Donato, 20097 San Donato Milanese (MI), Italy
12	Address for correspondence:
13	Luca Testa, MD, PhD
14	Department of Clinical and Interventional Cardiology, IRCCS Policlinico San Donato
15	Piazza Edmondo Malan 2, 20097 San Donato Milanese (Milano), Italy.
16	Email: <u>luctes(<i>w</i>gmail.com</u>
18	Text word count: 5000

19

20 Short title: The CAPTURE registry

21 Abstract

Background: The incidence and possible implications of coronary artery anomalies (CAA) in
patients undergoing transcatheter aortic valve replacement (TAVR) are uncertain.

Aims: To evaluate the impact of CAA on TAVR outcomes, and to suggest possible strategies to

25 prevent CAA related complications.

26 Methods: Among 2,164 consecutive patients who underwent TAVR in our center, 15 (0.69%) were

27 identified to have a CAA, based on pre-operative Computed Tomography (CT) scans.

28 **Results**: CT-angiography revealed the following features of CAA: the majority of anomalous CAA

29 concerned the right coronary artery (80%), followed by the left main (13.3%) and the left

30 circumflex (6.7%). An intramural course was observed only in 26.7% patients, whereas an acute

31 take-off was detected in more than half of the study cohort (53.3%). High-risk sudden cardiac death

- 32 features were observed in 6 (40%) patients.
- Technical success was 86.7%, device success was 80%. One patient experienced a cardiac arrest 15 minutes after procedure, resulting from occlusion of the anomalous right coronary artery with the ostium located at the right-to-non coronary commissure. There were no cases of \geq moderate paravalvular leak or stroke. One non-cardiac related death was recorded 4 months after the procedure.

38 Conclusions: The interaction between transcatheter bioprosthesis and different CAA types could
39 lead to ominous sequelae, if not promptly recognized and treated accordingly.

40

41 Keywords

42 Coronary artery anomalies; TAVI; bioprosthesis; aortic valve replacement; aortic stenosis.

43

44 Abbreviations list

- 45 BEV, balloon-expandable valve; CAA, coronary artery anomalies; CT, Computed Tomography;
- 46 LAD, left anterior descending; LCx, left circumflex artery; LSV, left sinus of Valsalva; PVL,
- 47 paravalvular leak; RCA, right coronary artery; RSV, right sinus of Valsalva; SAVR, surgical aortic
- 48 valve replacement; STJ, sino-tubular junction; TAVR, transcatheter aortic valve replacement; TTE,
- 49 transthoracic echocardiography; VARC-3, Valve Academic Research Consortium-3; SEV, self-
- 50 expanding valve.

51 Introduction

52 Coronary artery anomalies (CAA) are rare findings, often incidentally encountered. The most common phenotype is an anomalous origin from the aorta, 1 occurring in approximately 0.8% of 53 patients undergoing coronary artery angiography. However, if we exclude cases where the left 54 55 anterior descending (LAD) and left circumflex artery (LCx) have separated origins from the left sinus of Valsalva (LSV), the incidence drops to 0.2%.² The assessment of the risk of sudden cardiac 56 death and subsequent treatment is still a matter of debate due to limited data availability.³ 57 Nevertheless, there are few anomalies that could be injured during surgical aortic valve replacement 58 (SAVR), mainly LCx from right sinus of Valsalva (RSV) with a retro-aortic course.^{4,5} 59

In this variant, the peri-procedural is determined by the prosthesis compression or suture ligation.⁶ Surgeons have implemented different precautions to ensure the safety of surgical treatment, including the following: i) undersizing of the aortic valve bioprosthesis;^{5,7,8} ii) dissection of the LCx from the aortic annulus;^{8–10} iii) tilting of the bioprosthesis;¹¹ sutureless bioprosthesis, thanks to ligation risk absence and to inferior impact on the aortic anulus;¹² iv) supranular or stentless bioprosthesis implantation⁵ and/or v) revascularization only in case of overt ischemia, through coronary artery bypass grafting^{4,13} or drug eluting stent implantation.^{6,13}

67 Other anomalies can be treated with transection and re-implantation (e.g. RCA from LSV with 68 retro-aortic course)¹⁴ or with remodelling of the adjacent structure (e.g. pulmonary trunk and right 69 ventricle) to avoid compression (e.g. RCA from LSV with an inter-arterial course).¹⁵

Transcatheter aortic valve replacement (TAVR) has been established as an effective treatment for patients with severe aortic stenosis ¹⁶. Since the number of TAVR cases is meant to grow with the expansion of the indication to younger and lower risk patients, the likelihood of performing TAVR in the presence of a CAA should consistently increase.

The aim of the study is to evaluate the incidence and clinical implications of CAAs in patients
undergoing TAVR, and to propose possible management algorithms.

76 Methods

77 Study design and data collection

98

78	This observational retrospective single-center study analyzed all consecutive patients with
79	evidence of CAA who underwent TAVR procedure from July 2015 to March 2023 at our Center.
80	Inclusion criteria were: 1- detection of CAA at pre-TAVR computed tomography (CT) scan; 2-
81	patient with severe aortic stenosis of a native valve or degenerated bioprosthesis with an indication
82	for transcatheter treatment. Exclusion criteria was previous cardiac surgery for CAA re-
83	implantation.
84	Data regarding baseline clinical and echocardiographic characteristics, CT scan, procedural
85	features, as well as follow-up at 30 day and 1 year, were collected into our electronic prospective
86	institutional database.
87	Patients were deemed suitable for TAVR after Heart Team evaluation, and they all provided written
88	informed consent for the procedure.
89	The study complied with the Declaration of Helsinki. The local ethics committees approved the use
90	of retrospective anonymized data for this study.
91	
92	CT scan and transthoracic echocardiography
93	CT-angiography scans were performed on 64- or 128-row electrocardiography gated multidetector
94	scanner (Somatom Definition; Siemens healthcare, Forchheim, Germany). The 3-Mensio valves
95	software (version 8.2, Pie Medical Imaging, Maastricht, The Netherlands) enabled multiplanar
96	reconstruction analysis of the aortic root and of the coronary arteries, evaluating both the diastolic
97	and systolic phases. ¹⁷ The following features of coronary arteries were evaluated: i) take-off level,

99 course, pre-pulmonic, inter-arterial, sub-pulmonic, retro-aortic or retro-cardiac; iv) ostia type,

below or above a rtic valve commissure; ii) take-off angle, acute ($<45^{\circ}$) or non-acute ($\geq 45^{\circ}$); iii)

separate, shared or branch vessel; v) proximal tract morphology, normal, oval or slit-like and vi)

evidence of intramural location, as suggested by Cheezum et al.¹⁸, allowing to plan a strategy to
avoid negative interaction with TAVR devices. Measurements were made by a dedicated laboratory

103 of radiology technicians.

104 Oversizing was determined as: calculated perimeter oversizing (%) = [(prosthesis perimeter/CT
105 valve perimeter -1) *100].

106 Transthoracic echocardiography (TTE) was performed pre- and post-procedural, the latter 107 repeated at discharge. Post-procedural paravalvular leak (PVL) was arranged evaluated by 108 experienced echocardiographers, according to Valve Academic Research Consortium-3 (VARC-3) 109 criteria.¹⁹

110

111 *TAVR procedure*

112 Transfemoral TAVR was performed under local anesthesia. Conscious sedation was added 113 according to patient's tolerance. The type of bioprosthesis was selected by the first operator based 114 on the CT scan images.

115

116 Study end-points

Technical success was defined in accordance with VARC-3 criteria as: i) freedom from mortality; ii) successful access, delivery of the device, and retrieval of the delivery system; iii) correct positioning of a single prosthetic heart valve into the proper anatomical location and iv) freedom from surgery or intervention related to the device (permanent pacemaker implantation excluded), or to a major vascular or access-related, or cardiac structural complication.

Device success at 30 days was referred to the attainment of technical success and the fulfillment of the following situations: i) freedom from mortality; ii) freedom from surgery or intervention related to device (permanent pacemaker implantation excluded), major vascular, access-related or cardiac structural complication; and iii) intended performance of the valve, as mean gradient <20 mmHg, peak velocity <3 m/s, Doppler velocity index \geq 0.25, and less than moderate aortic regurgitation.¹⁹

129 Statistical analysis

Categorical and dichotomous variables are displayed as frequencies and percentages,
meanwhile, continuous variables are reported as mean and standard deviation, or median and
interquartile range, as appropriate.

Analyses were performed using SPSS statistical analysis software version 28.0 (IBM
Corporation, Armonk, NY, USA).

135 **Results**

136 *Baseline characteristics*

Among the last 2,164 patients treated by means of TAVR, only 15 (0.69%) were identified to
have a CAA on pre-operative CT scan.

The mean age was 83.7 ± 7.9 years, and the majority were female (80.0%). Mean STS score was 4.0 ± 2.8 . One patient (ID 10) had prior SAVR with a Trifecta 23 bioprosthesis, meanwhile 2 patients (20%) suffered of coronary artery disease. Of those, one (ID 2) had previous coronary artery bypass surgery with evidence of occlusion of the saphenous graft for the anomalous RCA, whereas the other one (ID 7) suffered from a chronic total occlusion of the anomalous RCA due to intrastent restenosis in the middle and proximal tract.

145 CT-angiography identified CAA features: most anomalies affected RCA (80%), with LM 146 (13.3%) and LCx (6.7%) to follow. Intramural course was observed only in 4 patients (26.7%), 147 meanwhile, acute take-off was detected in more than half (53.3%) of the study cohort. Ostia with 148 high-risk sudden cardiac death features (oval or slit like) were observed in 6 patients (40%), as 149 shown in *Table 1 and Suppl Table 1*.

150

151 Procedural data and outcomes

All the procedures were performed through trans-femoral approach and in 3 cases the procedure was performed with an embolic cerebral protection system. Rate of predilatation was 66.7%, meanwhile postdilation was performed only in 20% of patients. Three patients received a

balloon expandable valve (BEV). Only one (ID 2) patient required femoral artery stenting due to 155 main access vascular complication (Table 2 and Suppl Table 2). 156 157 Minimal oversizing was achieved, with an overall median oversizing of 11% [5%-17%]. 158 One patient (ID 11) experienced cardiac arrest 15 minutes after the end the procedure, due to 159 anomalous RCA occlusion (height 14 mm). The phenotype was a CAA originating from a 160 commissure and necessitated bailout emergency coronary artery stenting with Impella (®Abiomed) mechanical ventricular assist device. Of note, the CT scan finding was underestimated due to lack 161 162 of data: a high frame valve was implanted without coronary protection and with 5 mm implantation 163 depth, postdilatation was performed and no final selective CAA angiography was conducted. 164 *Table 3* shows which valve and size has been used for each CAA phenotype. Technical success was (86.7%), due to a cardiac arrest and a main access vascular 165 complication, whereas device success at 30 days was lower (80%), due to the two cases of technical 166 167 unsuccess and one case of aortic valve mean gradient >20 mmHg. There was no evidence of \geq moderate PVL and of cerebral strokes. One patient deceased 4 months after the procedure, due to 168 169 non-cardiac related causes (Table 2). 170

171 **Discussion**

172 CAAs are rare but increasingly recognized by cardiac imaging, and a wide spectrum of alteration
173 can be observed.²⁰ The phenotypes observed in elderly patients undergoing TAVR are usually
174 benign, even if CAAs show high-risk features.²¹

175 The main findings of this study can be summarized as follows:

176 1) the incidence of a CAA in patients undergoing TAVR is rare, below 1% of the cases;

177 2) myocardial infarction represents a major concern in patients with CAA undergoing TAVR as

178 having an incidence of 6.7%: a meticulous risk assessment using CT scan is imperative.

179 To the best of our knowledge, this is the largest cohort of patients with a CAA undergoing TAVR,

and a number of technical considerations can be done based on the cases performed; as such, we

hereby propose a classification, based on phenotypes of CAA, and two algorithms aimed at
preventing possible CAA related complications.

The first group is composed by patients deemed "at risk of ab extrinseco CAA compression", due to 183 184 valve implantation (*Central Illustration A*). In this subset of patients, occlusion of coronary arteries 185 with a retroaortic course is the most common complication described in literature, due to the strict 186 anatomical relationship between the CAA and the aortic root, where the radial forces generated by the bioprosthesis are exerted ²²⁻²⁵ An interarterial course is more common and theoretically 187 188 associated with a lower risk of compression due to the shorter vessel segment at risk (to be evaluated case by case) $^{26-28}$. The intramural course can be combined with the previous ones and it is 189 the least described in literature,²⁹ probably due to the low impact on coronary artery perfusion in 190 patients who did not show sudden cardiac death in a lifelong. 191

192 There are a few strategies described in literature to avoid CAA compression:

193 1) to assess the effective risk with an aortogram taken during balloon predilatation.^{24,26,27}

As a matter of fact, this procedure is not performed as a routine practice, but it is reserved only for patients exhibiting high-risk features (e.g. retro-aortic course). Additionally, predilatation with selective CAA angiography is feasible;²³ however it is technically more demanding and entails the risk of proximal vessel injury.

198 2) the use of self-expandable valves (SEV) which have the capability to be recaptured, thus 199 allowing for valve removal in cases of relevant overt compression.^{24,29,30} In our study, recapturable 200 devices were used in 9 out of 15 patients: low radial force SEV,³¹ such as the Portico³² and Acurate 201 Neo, have the advantage of exerting lesser impact on the aortic root with minimal deformation.

202 In our series, low radial force SEV were utilized in 6/15 patients.

203 3) the use of BEV that, unlike SEV, do not keep generating forces on the aortic root after

deployment.²⁷ BEV was used in 3 out of 15 patients.

4) Bioprosthesis undersizing allows lower stress and aortic anulus deformation. Oversizing in high-

206 risk features is always not recommended,²²

5) coronary protection with the chimney technique, especially when there is evidence of CAA obstruction during balloon valvuloplasty, in order to quickly deal with the abrupt coronary occlusion.³³ In our series it was performed in 2/15 patients.

210

The second group is composed by patients deemed "at risk of CAA ostium occlusion" (*Central Illustration B*). Historically, CAA originating from the commissure between two cusps have not been considered at risk for coronary occlusion: this is true when the aortic root is large enough to accommodate the bioprosthesis and still there is enough space between the latter and the coronary ostium. This measure is typically evaluated while planning a VIV procedure, i.e. the "VTC: valveto-coronary". Of note, there is no standard reference to consider in case of a CAA^{33,34}

217 In our sample, 1 patient over 4 experienced an acute CAA occlusion.

218 Consequently, we propose the following strategies:

219 1) mild "intentional" misalignment, to avoid placing a strut in front of the CAA ostia.³³ In our series

the only valve that could be deliberately misaligned were the Acurate Neo and Evolut. However,

221 being a retrospective study, it was not systematically used.

222 2) Low frame valve deployment (BE might be appropriate), to lessen the interaction of the upper223 crown with leaflets and CAA ostium (1/4 patients).

3) A slightly deeper implantation, to reduce leaflets eversion although it may increase the risk of
 conduction disturbances.³⁵

4) Coronary protection thorough the chimney technique, as described previously. We suggestperforming this technique in anatomies with highest risk of occlusion.

Additional general strategies for these two groups are: i) avoidance of postdilatation, if feasible (20% patients in our sample), in order to avoid further stress on the aortic root and eventual compression and ii) final selective CAA angiography^{31,34} to verify patency of the CAA (3/15 in our sample).

The final group consists of patients at "high risk of impaired CAA re-access". This group encompasses (a) CAA located above the sino-tubular junction (STJ), as well as (b) CAA originating from the commissure and (c) from the opposite sinus of Valsalva (*Central Illustration C*) where the distance is enough to make an abrupt occlusion of the coronary artery unlikely but still the cannulation might be cumbersome. For the latter two types, the suggested strategies for preventing CAA ostium occlusion remain the same. However, there are two main strategies that we suggest to preserve coronary re-access in a CAA above the STJ:

1) use of a valve with a lower height than the origin of the CAA (ID 9: in this case it was not

applied due to the patient's age of 90 years old and no coronary artery disease), and

242 2) use of an open frame valve, as the Acurate Neo (ID 6). Both strategies are intended to avoid the243 interference of the upper crown with catheters.

244

To systematically evaluate and manage the possible consequences of the presence of a CAA during TAVR, we hereby present two algorithms.

The first algorithm is based on the mechanism of CAA flow impairment, and it is described in *Figure 1*. Firstly, if the patient belongs to group 1 (risk of ab extrinseco compression), balloon predilatation with concomitant angiography should be performed. The subsequent strategy depends on the presence of compression. If the patient is in group 2 (risk of coronary ostium occlusion), the strategies will be different according to the type of CAA (commissural origin vs. low origin from opposite sinus of Valsalva). General strategies for both groups are avoidance of postdilatation and final selective CAA angiography.

The second algorithm is based on the risk of impaired coronary re-access (group 3), as shown in *Figure 2*. Strategies are different based on the phenotype: origin above the STJ, commissural origin and low origin from opposite sinus of Valsalva.

257

258 **Study limitations**

259	Data analysis has been conducted retrospectively and the small number of patients did not
260	allow more extensive data investigation.
261	Due to CAA rarity and their heterogeneity, the results of the analysis still must be considered
262	exploratory; further studies applying the proposed algorithms are needed for a thorough validation.
263	
264	
265	Conclusions
266	The presence of a CAA may significantly increase the risk of threatening complications during
267	TAVR. The possible interaction between the transcatheter bioprosthesis and the different CAA types
268	should be comprehensively evaluated upfront and the procedure planned accordingly.
269	
270	Acknowledgements
271	None
272	Sources of funding
273	This work was supported by IRCCS Policlinico San Donato, a clinical research hospital partially
274	funded by the Italian Ministry of Health.
275	Disclosures
276	Francesco Bedogni is consultant for Medtronic, Abbott, and Boston Scientific; Luca Testa is
277	consultant for Abbott, Meril, Medtronic and Boston Scientific. The other authors declare no conflict
278	of interest.

279 References

- 280 1. Gentile F, Castiglione V, De Caterina R. Coronary Artery Anomalies. *Circulation*. 2021;144(12):983–996.
- 281 2. Yildiz A, Okcun B, Peker T, Arslan C, Olcay A, Bulent Vatan M. Prevalence of coronary artery anomalies
- in 12,457 adult patients who underwent coronary angiography. *Clinical cardiology*. 2010;33(12).
- 283 3. Baumgartner H, de Backer J, Babu-Narayan S V., Budts W, Chessa M, Diller GP, Iung B, Kluin J, Lang

284 IM, Meijboom F, Moons P, Mulder BJM, Oechslin E, Roos-Hesselink JW, Schwerzmann M, et al. 2020 ESC

- 285 Guidelines for the management of adult congenital heart disease. *European heart journal*. 2021;42(6):563–645.
- 4. Vaishnava P, Pyo R, Filsoufi F, Sharma S. Compression of an anomalous left circumflex artery after aortic
 and mitral valve replacement. *The Annals of thoracic surgery*. 2011;92(5):1887–1889.
- 5. Pellicano M, Toth G, Di Gioia G, Rusinaru D, Wijns W, Barbato E, De Bruyne B, Degrieck I, Van Mieghem C. Unrecognized anomalous left circumflex coronary artery arising from right sinus of Valsalva: a source of perioperative complication. *Journal of cardiovascular medicine (Hagerstown, Md.).* 2016;17 Suppl 2:e228–e230.
- 292 6. López Castillo M, Martín Reyes R, Palfy J, Franco JA, Piñero A, Navarro F, Tomás M, Aldámiz G, Farré

293 J. Successful Treatment of Compression of an Anomalous Circumflex Artery After Aortic Valve Replacement

294 With Percutaneous Coronary Intervention. JACC. Cardiovascular interventions. 2016;9(15):1629–1630.

- 7. Yokoyama S, Takagi K, Mori R, Aoyagi S. Aortic valve replacement in patients with an anomalous left
 circumflex artery: technical considerations. *Journal of cardiac surgery*. 2012;27(2):174–177.
- 297 8. Castillo JG, Sanz J, Fischer GW, Bowman K, Filsoufi F. Management of anomalous left circumflex artery
 298 encircling the aortic annulus in a patient undergoing multivalvular surgery. *Journal of cardiac surgery*.
 299 2009;24(6):667–669.
- 9. Flores RM, Byrne JG. Aortic valve replacement with an anomalous left circumflex coronary artery
 encircling the aortic anulus. *The Journal of thoracic and cardiovascular surgery*. 2001;121(2):396–397.
- 302 10. Liebrich M, Tzanavaros I, Scheid M, Voth W, Doll KN, Hemmer WB. Aortic valve/root
 303 procedures in patients with an anomalous left circumflex coronary artery and a bicuspid aortic valve: anatomical
 and technical implications. *Interactive cardiovascular and thoracic surgery*. 2015;21(1):114–116.
- 305 11. Umakanthan R, Brewer ZE, Byrne JG, Ahmad RM. Use of the hybrid operating room for aortic
 306 valve replacement in a patient with anomalous left circumflex artery. *The Journal of thoracic and cardiovascular* 307 *surgery*. 2010;139(6).

- 30812.Harky A, Hof A, Ahmad MU, Uppal R. Incidental finding of anomalous circumflex coronary
- artery from right coronary sinus prior to aortic valve surgery. *BMJ case reports*. 2017;2017.
- 31013.Alameddine AK, Binnall BJ, Conlin FT, Broderick PJ. Aortic Valve Replacement in 8 Adults
- 311 with Anomalous Aortic Origin of Coronary Artery. *Texas Heart Institute journal*. 2019;46(3):189–194.
- 312 14. Inan K, Ucak A, Onan B, Tamtekin B, Temizkan V, Yilmaz AT. Posterior root enlargement for
- 313 aortic valve replacement associated with unexpected anomalous right coronary artery. Journal of cardiac surgery.
- 314 2010;25(1):92–95.
- 315 15. Roughneen PT, Al-Dossari GA. The Anomalous Coronary Artery in Aortic Valve Replacement: A
 316 Case For Caution. *The Annals of thoracic surgery*. 2016;102(2):e113–e115.
- 317 16. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, Capodanno D, Conradi

L, De Bonis M, De Paulis R, Delgado V, Freemantle N, Gilard M, Haugaa KH, Jeppsson A, et al. 2021

319 ESC/EACTS Guidelines for the management of valvular heart disease. European heart journal. 2022;43(7):561-

320 632.

Jilaihawi H, Kashif M, Fontana G, Furugen A, Shiota T, Friede G, Makhija R, Doctor N, Leon
 MB, Makkar RR. Cross-sectional computed tomographic assessment improves accuracy of aortic annular sizing
 for transcatheter aortic valve replacement and reduces the incidence of paravalvular aortic regurgitation. *Journal of the American College of Cardiology*. 2012;59(14):1275–1286.

18. Cheezum MK, Liberthson RR, Shah NR, Villines TC, O'Gara PT, Landzberg MJ, Blankstein R.
 Anomalous Aortic Origin of a Coronary Artery From the Inappropriate Sinus of Valsalva. *Journal of the American College of Cardiology*. 2017;69(12):1592–1608.

328 19. Généreux P, Piazza N, Alu MC, Nazif T, Hahn RT, Pibarot P, Bax JJ, Leipsic JA, Blanke P,
329 Blackstone EH, Finn MT, Kapadia S, Linke A, Mack MJ, Makkar R, et al. Valve Academic Research Consortium
330 3: Updated Endpoint Definitions for Aortic Valve Clinical Research. *Journal of the American College of*331 *Cardiology*. 2021;77(21):2717–2746.

332 20. Villa AD, Sammut E, Nair A, Rajani R, Bonamini R, Chiribiri A. Coronary artery anomalies
333 overview: The normal and the abnormal. *World journal of radiology*. 2016;8(6):537.

334 21. Gräni C, Benz DC, Steffen DA, Clerc OF, Schmied C, Possner M, Vontobel J, Mikulicic F, 335 Gebhard C, Pazhenkottil AP, Gaemperli O, Hurwitz S, Kaufmann PA, Buechel RR. Outcome in middle-aged 336 individuals with anomalous origin of the coronary artery from the opposite sinus: a matched cohort study.

European heart journal. 2017;38(25):2009–2016.

Acosta-Vélez JG, Del Blanco BG, Guindo J, Serrano JM, Calabria HC, Aguasca GM, GonzalezAlujas T, Durán I, Tornos P. Acute artery occlusion during transcatheter aortic valve replacement in a patient with
an anomalous origin of the circumflex artery. *JACC. Cardiovascular interventions*. 2014;7(11):1324–1325.
Tabachnick D, Obokhae B, Harrington K, Brown DL. Assessing the risk of an anomalous

342 circumflex artery using balloon aortic valvuloplasty prior to transcatheter aortic valve replacement.
343 *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography &*344 *Interventions*. 2020;96(2):497–499.

345 24. Mennuni MG, Pagnotta P, Presbitero P. Percutaneous aortic valve implantation in severe stenosis
346 associated with anomalous origin of the circumflex coronary artery. *European heart journal*. 2011;32(13):1687.

347 25. Mizote I, Conradi L, Schäfer U. A case of anomalous left coronary artery obstruction caused by
348 lotus valve implantation. *Catheterization and cardiovascular interventions : official journal of the Society for*349 *Cardiac Angiography & Interventions*. 2017;90(7):1227–1231.

350 26. Giri J, Szeto WY, Bavaria J, Herrmann HC. Transcatheter aortic valve replacement with coronary
351 artery protection performed in a patient with an anomalous left main coronary artery. *Journal of the American*352 *College of Cardiology*. 2012;60(6).

Weich H, Ackermann C, Viljoen H, Van Wyk J, Mabin T, Doubell AF. Transcatheter aortic valve
 replacement in a patient with an anomalous origin of the right coronary artery. *Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions*. 2011;78(7):1013–1016.

Birkl K, Plank F, Bonaros N, Feuchtner G, Friedrich G. Transcatheter Aortic Valve Repair in a
Patient With Anomalous Right Coronary Artery Originating From the Left Aortic Sinus and Myelodysplastic
Syndrome. *Cureus*. 2020;12(7).

Marcus GU, Orbach A, Fremes S, Vijayaraghavan R, Kerner A, Oikonomou A, Roifman I,
Wijeysundera HC. TAVR in a Patient With Anomalous Origin and Course of the Left Main Coronary Artery. *JACC. Case reports*. 2022;4(22):1467–1471.

362 30. Cho SW, Kim BG, Park TK, Choi SH, Gwon HC, Park SJ, Nah JC. Transcatheter aortic valve
363 replacement in a patient with anomalous origin of the left coronary artery. *Journal of cardiology cases*.
364 2019;19(4):133–135.

365 31. Tzanis G, Ancona M, Romano V, Bellini B, Sgura F, Montorfano M. TAVR in a patient with an
anomalous left main: Self-expanding prosthesis might be the preferred choice. *Hellenic journal of cardiology : HJC = Hellenike kardiologike epitheorese*. 2020;61(5):344–345.

- 368 32. Gorla R, Oliva OA, Poletti E, Finotello A, Morganti S, Zannoni J, Agnifili M, Barletta M,
- 369 Squillace M, Criscione E, Tusa M, Brambilla N, Auricchio F, Testa L, Bedogni F. Impact of Nodular
- 370 Calcifications in the Aortic Annulus and Left Ventricular Outflow Tract on TAVI Outcome with New-Generation
- 371 Devices. *Reviews in Cardiovascular Medicine*. 2022;23(11).
- 372 33. Costa G, Sgroi C, Strazzieri O, Reddavid C, Valvo R, Motta S, Frittitta V, Dipietro E, Tamburino
- 373 C, Barbanti M. Intentional Misalignment of a Transcatheter Aortic Valve to Preserve Reaccess to Coronaries of
- Anomalous Origin. JACC. Case reports. 2022;4(2):83-86.
- 375 34. Geyer M, Tamm AR, Da Rocha E Silva JG, Gori T, Münzel T, Von Bardeleben RS. Beware of the
- 376 commissure transcatheter aortic valve replacement in a rare anomaly of the left main coronary. Journal of

377 cardiovascular medicine (Hagerstown, Md.). 2022;23(7):477–478.

- 378 35. Casenghi M, Oliva OA, Squillace M, Bellamoli M, Poletti E, Popolo Rubbio A, Testa L, Bedogni
- 379 F, De Marco F. Bailout From Sinus Jailing: In-Series TAVR-in-TAVR to Avoid Coronary Flow Obstruction.
- 380 JACC. Case reports. 2021;3(4):678–681.
- 381
- 382

Table 1. Baseline characteristics of patients with CAA who underwent TAVR.

Variables		Overall (N=15)
Clinical characteristics	Age (years)	83.7 ± 7.9
	Female sex	12 (80.0%)
	Hypertension	10 (66.7%)
	Diabetes	2 (13.3%)
	Dyslipidemia	8 (53.3%)
	COPD	3 (6.7%)
	Coronary artery disease	2 (13.3%)
	Prior cardiac surgery	2 (13.3%)
	Prior CABG	1 (6.7%)
	Prior PCI	1 (6.7%)
	Prior AMI	2 (13.3%)
	STS score (%)	4.0 ± 2.8
Laboratory and TTE	Creatinine clearance (mL/min/1.73 m2)	61.9 ± 20.6
5	Haemoglobin (g/dL)	12.7 ± 1.8
	Ejection fraction (%)	55.3 ± 9.6
	Mean aortic gradient (mmHg)	45.2 ± 15.0
	AR ≥moderate	4 (26.7%)
Aortic valve CT scan evaluation	Annulus min diameter (mm)	20.5 ± 2.5
	Annulus max diameter (mm)	25.1 ± 2.8
	Annulus mean diameter (mm)	22.8 ± 2.6
	Annulus perimeter (mm)	72.0 ± 8.0
	Annulus area (mm2)	406.7 ± 87.6
	Sinus of Valsalva diameter (mm)	31.4 ± 2.5
	Calcium volume 800 HU (mm3)	256.8 [100.0-382.9]
	Aortic angulation (°)	46.3 ± 9.6
	Index of eccentricity	0.18 ± 0.06
	LVOT diameter (mm)	22.5 ± 3.3
	Ascending aorta (mm)	28.3 ± 3.6
CAA CT scan evaluation	LM height (mm)	13.4 ± 2.9
	RCA height (mm)	18.5 ± 3.2
	Anomalous RCA	12 (80.0%)
	Anomalous LCx	1 (6.7%)
	Anomalous LM	2 (13.3%)
	Intramural course	4 (26.7%)
	Oval ostium	4 (26.7%)
	Slit-like ostium	2 (13.3%)
	Acute take-off	8 (53.3%)

Values expressed as mean±SD, median (25th÷75th percentile) or N (%). AMI, acute myocardial infarction; AR, aortic regurgitation; CAA, coronary artery anomalies; CABG, coronary artery bypass grafting; COPD, chronic obstructive pulmonary disease; CT, computed tomography; HU, Hounsfield Units; LM, left main; LVOT, left ventricular outflow tract; PCI, percutaneous coronary intervention; RCA, right coronary artery; STS, Society of

Thoracic Surgeons; TTE transthoracic echocardiography.

384

Variables		Overall (N=15)
Procedure	Femoral route	15 (100.0%)
	Subclavian route	0 (0.0%)
	Embolic protection system	3 (20.0%)
	Any vascular complications	1 (6.7%)
	PTA with stenting of access site	1 (6.7%)
	PCI with stenting	1 (6.7%)
	Predilatation	10 (66.7%)
	Postdilatation	3 (20.0%)
	Emergent cardiac surgery	0 (0.0%)
	Need for second valve	0 (0.0%)
	Contrast volume (mL)	173.8 ± 57.8
	Fluoroscopy time (min)	21.2 ± 9.8
Outcomes	Ejection fraction (%)	56.6 ± 11.1
	Mean gradient (mmHg)	8.2 ± 4.4
	PVL absent/trivial	5 (33.3%)
	PVL mild	10 (66.7%)
	PVL >moderate	0 (0.0%)
	Technical success	13 (86.7%)
	Device success (at 30 days)	12 (80.0%)
	PPI	1 (6.7%)
	Stroke (including not disabling)	0 (0.0%)
	30-day mortality	0 (0.0%)
	1-year mortality	1 (11.1%)

Table 2. Procedural and follow up data of patients with CAA who underwent TAVR.

Values expressed as mean±SD, median (25th÷75th percentile) or N (%). LCC, left coronary cusp; NCC, noncoronary cusp; PCI, percutaneous coronary intervention; PPI, permanent pacemaker implantation; PTA, percutaneous transluminal angioplasty; PVL, paravalvular leak.

Patient ID	Anomalous CA	Anomalous origin	Course	Intramural tract	TAVR prosthesis	Size
1	LCx	RSV	Retro-aortic	No	Portico	25
2	RCA	LSV	Inter-arterial	Yes	Myval	26
3	RCA	LSV	Inter-arterial	No	Acurate Neo	М
4	RCA	LSV	Inter-arterial	No	Evolut-R	26
5	RCA	LSV	Inter-arterial	No	Acurate Neo	S
6	RCA	Above STJ	Inter-arterial	No	Acurate Neo	S
7	RCA	RCC-LCC commissure	Inter-arterial	No	Evolut-R	26
8	LM	NCC-LCC commissure	Retro-aortic	No	Myval	27,5
9	RCA	Above STJ	Inter-arterial	No	Evolut-R	26
10	RCA	LSV	Inter-arterial	Yes	Myval	23
11	RCA	RCC-NCC commissure	Inter-arterial	No	Evolut-PRO	29
12	RCA	LSV	Inter-arterial	Yes	Navitor	29
13	RCA	LSV	Inter-arterial	Yes	Evolut-R	34
14	LM	RSV	Retro-aortic	No	Portico	23
15	RCA	RCC-LCC commissure	Inter-arterial	No	Portico	25

389 Table 3. Data of CAA features and TAVR prosthesis choice.

CAA, coronary artery anomalies; LCC, left coronary cusp; LCx, left circumflex artery; LM, left main LSV, left sinus of Valsalva; NCC, non-coronary cusp; RCA, right coronary artery; RCC, right coronary cusp; RSV, right sinus of Valsalva; STJ, sino-tubular junction

391 Figure Titles and Legends





393 Central Illustration. Most common phenotypes of CAA in patients undergoing TAVR, 394 classified by mechanism of impairment. (A) Compression ab extrinseco (red). From left to right: 395 retroaortic course, intramural course and interarterial course (blue arrows to represent pulmonary 396 artery compression). (B) Ostium occlusion (purple). From left to right: commissural origin and low 397 origin from opposite SV. (C) Challenging re-access (blue). 1) above STJ origin; 2) commissural 398 origin and 3) low origin from opposite SV.



Figure 1. Algorithm for valve choice in patient with CAA undergoing TAVR, at risk of coronary occlusion. *Retroaortic, intramural and interarterial CAA have different risk of coronary compression and subsequent occlusion, but the anatomy must be assessed case-by-case. However, the algorithm is not affected, due to data paucity and unpredictable behavior in real world. §Placing of a neocommissure in front of the CAA ostium, through a custom projection, detected by CT scan. BEV, balloon-expandable valve; CAA, coronary artery anomaly; SEV, self-expandable valve; SV, sinus of Valsalva.





408 Figure 2. Algorithm for valve choice in patient with CAA who undergo TAVR, at risk of

- 409 impaired coronary re-access. §Placing of a neocommissure in front of the CAA ostium, through a
- 410 custom projection, detected by CT scan.
- 411 CAA, coronary artery anomaly; STJ, sino-tubular junction; SV, sinus of Valsalva.